Press Release: FDA Approves New Bladder Cancer Treatment

May 18, 2016
by Andrea Maddox-Smith

The Bladder Cancer Advocacy Network (BCAN) applauds the U.S. Food and Drug Administration (FDA) approval of an innovative, first-of-its-kind bladder cancer treatment, establishing a brand new class of therapy for the disease. Genentech, a member of the Roche Group, produced this new treatment, TECENTRIQ™ (atezolizumab), which allows the body’s immune system to work more effectively to fight cancer.

Read More...

Meet BCAN Volunteer Nancy Lindsey

May 17, 2016
by Jeanne Mahoney

I was diagnosed with bladder cancer in 2006. I had blood in my urine – the specialists thought of everything else possibly causing this — but I believed there was more to it. I got a second opinion, and then nine months later came a confirmation of bladder cancer.

Read More...